Alexion Pharmaceuticals Inc.
http://www.alexion.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alexion Pharmaceuticals Inc.
Zinc, Vitamin C Don't Reduce COVID-19 Symptoms; Impact On Shortening Colds Not Questioned
Trial with 214 adults with SARS-CoV-2 showed no significant difference among the treatment groups in number of days to symptom relief. Study didn’t measure zinc/vitamin C supplementation for shortening duration of colds.
Sanofi Genzyme’s Treatment For Pompe Disease On Track For EU Approval
EU reviewers have recommended marketing approval for two new medicines, but have turned down another product.
EU Decision Time On Broader Indication For AbbVie’s Skyrizi
The European Medicines Agency is meeting this week to consider applications to broaden the use of approved drugs to include new indications in the EU.
Finance Watch: $135m In Venture Capital Will Fund Amylyx’s Late-Stage ALS Drug
Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Alexion Pharma K.K. (formerly Legend K.K. or Legend Pharma Co., Ltd.) (Japan)
- AstraZeneca PLC
- Enobia Pharma Corp.
- Portola Pharmaceuticals, Inc. (PTLA)
- Synageva BioPharma Corp.
- Syntimmune, Inc.
- Taligen Therapeutics, Inc.
- Wilson Therapeutics AB